NASDAQ:SLGC SomaLogic (SLGC) Stock Forecast, Price & News $2.36 +0.02 (+0.85%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$2.27▼$2.4050-Day Range$1.99▼$2.4552-Week Range$1.92▼$3.79Volume1.24 million shsAverage Volume1.02 million shsMarket Capitalization$443.85 millionP/E RatioN/ADividend YieldN/APrice Target$5.40 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media SomaLogic MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside128.8% Upside$5.40 Price TargetShort InterestHealthy5.55% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.09Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.66) to ($0.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.22 out of 5 starsBusiness Services Sector150th out of 316 stocksCommercial Physical Research Industry7th out of 14 stocks 3.3 Analyst's Opinion Consensus RatingSomaLogic has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.40, SomaLogic has a forecasted upside of 128.8% from its current price of $2.36.Amount of Analyst CoverageSomaLogic has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.55% of the float of SomaLogic has been sold short.Short Interest Ratio / Days to CoverSomaLogic has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in SomaLogic has recently decreased by 16.42%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSomaLogic does not currently pay a dividend.Dividend GrowthSomaLogic does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLGC. Previous Next 2.3 News and Social Media Coverage News SentimentSomaLogic has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Business Services companies.News Coverage This WeekMarketBeat has tracked 6 news articles for SomaLogic this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for SLGC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added SomaLogic to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SomaLogic insiders have not sold or bought any company stock.Percentage Held by Insiders14.90% of the stock of SomaLogic is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.35% of the stock of SomaLogic is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for SomaLogic are expected to grow in the coming year, from ($0.66) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SomaLogic is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SomaLogic is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSomaLogic has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About SomaLogic (NASDAQ:SLGC) StockSomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.Read More SLGC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLGC Stock News HeadlinesSeptember 26, 2023 | americanbankingnews.comSomaLogic (NASDAQ:SLGC) Lowered to "Hold" at Canaccord Genuity GroupSeptember 26, 2023 | americanbankingnews.comSomaLogic (NASDAQ:SLGC) Receives "Hold" Rating from Canaccord Genuity GroupSeptember 29, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 19, 2023 | finance.yahoo.comSomaLogic and Korea’s DNA Link partner to bring the 7,000-plex SomaScan® platform to the fast-growing Asia-Pacific proteomics marketSeptember 12, 2023 | stockhouse.comSomaLogic researchers identify key proteins to aid in early detection of lung, colon and breast cancer and ovarian tumorsSeptember 5, 2023 | stockhouse.comSomaLogic expands agreement with Novo Nordisk to 2025August 18, 2023 | finance.yahoo.comSomaLogic, Inc. (NASDAQ:SLGC) Just Reported Earnings, And Analysts Cut Their Target PriceAugust 17, 2023 | finance.yahoo.comSomaLogic, Inc. (NASDAQ:SLGC) Q2 2023 Earnings Call TranscriptSeptember 29, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.August 15, 2023 | seekingalpha.comMore on SomaLogicAugust 15, 2023 | benzinga.comPaysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On TuesdayAugust 15, 2023 | msn.comWhy Shares of SomaLogic Are Up TuesdayAugust 14, 2023 | markets.businessinsider.comSomaLogic Reports Second Quarter 2023 Financial ResultsJuly 24, 2023 | finance.yahoo.comSomaLogic partners with Dante Genomics to enhance clinical and research adoption of proteomics in EuropeJune 16, 2023 | uk.sports.yahoo.comInstitutional investors may adopt severe steps after SomaLogic, Inc.'s (NASDAQ:SLGC) latest 11% drop adds to a year lossesJune 12, 2023 | msn.comSomaLogic, Citogen partner to expand authorized site program in EuropeJune 7, 2023 | finance.yahoo.comSomaLogic, Inc. (SLGC) Just Flashed Golden Cross Signal: Do You Buy?June 6, 2023 | markets.businessinsider.comSomaLogic CFO Shaun Blakeman ResignsJune 6, 2023 | finance.yahoo.comSomaLogic Announces Chief Financial Officer TransitionMay 24, 2023 | benzinga.comSomaLogic to Participate in the Jefferies Healthcare ConferenceMay 12, 2023 | marketwatch.com8-K: SomaLogic, Inc.May 11, 2023 | msn.comSomaLogic: Q1 Earnings InsightsMay 11, 2023 | finance.yahoo.comSomaLogic, Inc. (SLGC) Reports Q1 Loss, Tops Revenue EstimatesMay 5, 2023 | finance.yahoo.comFewer Investors Than Expected Jumping On SomaLogic, Inc. (NASDAQ:SLGC)April 26, 2023 | benzinga.comSomaLogic, Inc. (SLGC) Stock Investigation: Robbins LLP Reminds Investors it is Investigating SomaLogic, Inc.April 22, 2023 | uk.finance.yahoo.comSomaLogic, Inc. (SLGC) stock historical prices & data – Yahoo FinanceApril 22, 2023 | benzinga.comSomaLogic, Inc. (SLGC) Shareholder Investigation: Robbins LLP is Investigating SomaLogic, Inc. on behalf of ShareholdersSee More Headlines Receive SLGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SomaLogic and its competitors with MarketBeat's FREE daily newsletter. Email Address SLGC Company Calendar Last Earnings8/14/2023Today9/29/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryN/A SectorBusiness Services Current SymbolNASDAQ:SLGC CUSIPN/A CIK1837412 Webii.cmlifesciencesspac.com Phone303-625-9000FaxN/AEmployees451Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.40 High Stock Price Forecast$8.00 Low Stock Price Forecast$2.50 Forecasted Upside/Downside+128.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-109,160,000.00 Net Margins-139.23% Pretax Margin-139.94% Return on Equity-25.49% Return on Assets-22.27% Debt Debt-to-Equity RatioN/A Current Ratio16.39 Quick Ratio15.91 Sales & Book Value Annual Sales$97.67 million Price / Sales4.54 Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / Book0.79Miscellaneous Outstanding Shares188,070,000Free Float160,049,000Market Cap$443.85 million OptionableNot Optionable Beta1.67 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Stephen A. Williams BS (Age 63)MB, Ph.D., Chief Medical Officer Comp: $648.03kMr. Adam Taich (Age 48)Interim CEO Mr. Eliot M. Lurier CPA (Age 65)CPA, Interim Chief Financial Officer Mr. Pi Zheng (Age 50)Interim Chief Accounting Officer Dr. Jason Cleveland Ph.D.Chief Technology OfficerDr. Nebojsa Janjic Ph.D. (Age 62)Chief Science Officer Mr. Ruben Gutierrez J.D. (Age 48)Gen. Counsel Ms. Alison Marie Roelke (Age 48)Chief People Officer More ExecutivesKey CompetitorsLuna InnovationsNASDAQ:LUNANational ResearchNASDAQ:NRCTrueBlueNYSE:TBICantaloupeNASDAQ:CTLPRackspace TechnologyNASDAQ:RXTView All CompetitorsInstitutional OwnershipCalifornia State Teachers Retirement SystemBought 9,942 shares on 8/21/2023Ownership: 0.102%Boothbay Fund Management LLCSold 11,741 shares on 8/15/2023Ownership: 0.146%Alliancebernstein L.P.Bought 32,820 shares on 8/15/2023Ownership: 0.102%Wells Fargo & Company MNBought 29,922 shares on 8/15/2023Ownership: 0.035%Royal Bank of CanadaBought 13,543 shares on 8/15/2023Ownership: 0.013%View All Institutional Transactions SLGC Stock - Frequently Asked Questions Should I buy or sell SomaLogic stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SomaLogic in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SLGC shares. View SLGC analyst ratings or view top-rated stocks. What is SomaLogic's stock price forecast for 2023? 4 Wall Street research analysts have issued 1 year price objectives for SomaLogic's shares. Their SLGC share price forecasts range from $2.50 to $8.00. On average, they predict the company's stock price to reach $5.40 in the next twelve months. This suggests a possible upside of 128.8% from the stock's current price. View analysts price targets for SLGC or view top-rated stocks among Wall Street analysts. How have SLGC shares performed in 2023? SomaLogic's stock was trading at $2.51 at the beginning of 2023. Since then, SLGC shares have decreased by 6.0% and is now trading at $2.36. View the best growth stocks for 2023 here. Are investors shorting SomaLogic? SomaLogic saw a decrease in short interest in September. As of September 15th, there was short interest totaling 8,450,000 shares, a decrease of 16.4% from the August 31st total of 10,110,000 shares. Based on an average daily trading volume, of 931,800 shares, the short-interest ratio is presently 9.1 days. Approximately 5.6% of the shares of the company are sold short. View SomaLogic's Short Interest. When is SomaLogic's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our SLGC earnings forecast. How were SomaLogic's earnings last quarter? SomaLogic, Inc. (NASDAQ:SLGC) announced its quarterly earnings results on Monday, August, 14th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $0.05. The firm earned $20.47 million during the quarter, compared to the consensus estimate of $19.50 million. SomaLogic had a negative trailing twelve-month return on equity of 25.49% and a negative net margin of 139.23%. What ETF holds SomaLogic's stock ? ARK Genomic Revolution ETF holds 13,104,112 shares of SLGC stock, representing 1.22% of its portfolio. What guidance has SomaLogic issued on next quarter's earnings? SomaLogic issued an update on its FY 2023 earnings guidance on Monday, August, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $80.00 million-$84.00 million, compared to the consensus revenue estimate of $81.62 million. What is SomaLogic's stock symbol? SomaLogic trades on the NASDAQ under the ticker symbol "SLGC." How do I buy shares of SomaLogic? Shares of SLGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is SomaLogic's stock price today? One share of SLGC stock can currently be purchased for approximately $2.36. How much money does SomaLogic make? SomaLogic (NASDAQ:SLGC) has a market capitalization of $443.85 million and generates $97.67 million in revenue each year. The company earns $-109,160,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. How many employees does SomaLogic have? The company employs 451 workers across the globe. How can I contact SomaLogic? SomaLogic's mailing address is 667 MADISON AVENUE, NEW YORK NY, 10065. The official website for the company is ii.cmlifesciencesspac.com. The company can be reached via phone at 303-625-9000 or via email at investors@somalogic.com. This page (NASDAQ:SLGC) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SomaLogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.